Mayne Pharma Limited - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: MC9B64C68BCEN
Leaflet:

Download PDF Leaflet

Mayne Pharma Limited - Product Pipeline Review - Q4 2010
Summary

Global Market Direct’s pharmaceuticals report, “Mayne Pharma Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Mayne Pharma Limited - company overview including business description, key employees, and other facts.
- Review of current pipeline of Mayne Pharma Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Mayne Pharma Limited with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Mayne Pharma Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mayne Pharma Limited’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Mayne Pharma Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mayne Pharma Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mayne Pharma Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mayne Pharma Limited and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 MAYNE PHARMA LIMITED SNAPSHOT

3.1 Business Description

4 MAYNE PHARMA LIMITED- RESEARCH AND DEVELOPMENT OVERVIEW

4.1 Key Therapeutic Areas

5 MAYNE PHARMA LIMITED- PIPELINE REVIEW

5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities

6 MAYNE PHARMA LIMITED PIPELINE PRODUCTS GLANCE

6.1 Mayne Pharma Limited Phase II Pipeline
6.2 Mayne Pharma Limited Phase I Pipeline
6.3 Mayne Pharma Limited Pre-Clinical Pipeline

7 MAYNE PHARMA LIMITED - DRUG PROFILES

7.1 Product
  7.1.1 Product Description
  7.1.2 Mechanism of Action
  7.1.3 R&D Progress

8 MAYNE PHARMA LIMITED PIPELINE ANALYSIS

8.1 Mayne Pharma Limited Pipeline Products by Therapeutic Class
8.2 Mayne Pharma Limited Pipeline Products by Target
8.3 Mayne Pharma Limited Pipeline by Route of Administration
8.4 Mayne Pharma Limited Pipeline Products by Molecule Type

9 MAYNE PHARMA LIMITED- RECENT PIPELINE UPDATES
10 MAYNE PHARMA LIMITED- DORMANT PIPELINE PROJECTS

10.1 Feature on Dormant Projects

11 MAYNE PHARMA LIMITED- DISCONTINUED PIPELINE PRODUCTS

11.1 Discontinued Pipeline Product Profiles
  11.1.1 Product

12 MAYNE PHARMA LIMITED – FEATURED NEWS
13 MAYNE PHARMA LIMITED STATEMENT

13.1 Mayne Pharma Limited - Locations and Subsidiaries

14 APPENDIX

14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer

LIST OF TABLES

Table 1: Mayne Pharma Limited - Key Information
Table 2: Mayne Pharma Limited - Key Facts
Table 3: Mayne Pharma Limited - Key Therapeutic Areas
Table 4: Mayne Pharma Limited - Pipeline by Stage of Development,
Table 5: Mayne Pharma Limited - Monotherapy Products in Pipeline,
Table 6: Mayne Pharma Limited - Combination Treatment Modalities in Pipeline,
Table 7: Mayne Pharma Limited - Phase II Pipeline,
Table 8: Mayne Pharma Limited - Phase I Pipeline,
Table 9: Mayne Pharma Limited - Pre-Clinical Pipeline,
Table 10: Mayne Pharma Limited - Pipeline By Therapeutic Class
Table 11: Mayne Pharma Limited - Pipeline By Target
Table 12: Mayne Pharma Limited - Pipeline By Route of Administration
Table 13: Mayne Pharma Limited - Pipeline By Molecule Type
Table 14: Mayne Pharma Limited - Recent Pipeline Updates
Table 15: Mayne Pharma Limited - Dormant Pipeline Projects

LIST OF FIGURES

Figure 1: Mayne Pharma Limited - Research and Development Overview
Figure 2: Mayne Pharma Limited - Pipeline by Stage of Development,
Figure 3: Mayne Pharma Limited - Monotherapy Products in Pipeline,
Figure 4: Mayne Pharma Limited - Combination Treatment Modalities in Pipeline,
Figure 5: Mayne Pharma Limited - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Mayne Pharma Limited - Pipeline By Therapeutic Class
Figure 7: Mayne Pharma Limited - Pipeline By Target and Stage of Development
Figure 8: Mayne Pharma Limited - Pipeline By Target
Figure 9: Mayne Pharma Limited - Pipeline By Route of Administration and Stage of Development
Figure 10: Mayne Pharma Limited - Pipeline By Route of Administration
Figure 11: Mayne Pharma Limited - Pipeline By Molecule Type and Stage of Development
Figure 12: Mayne Pharma Limited - Pipeline By Molecule Type

COMPANIES MENTIONED

Mayne Pharma Limited

Ask Your Question

Mayne Pharma Limited - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: